Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers and Risk Prediction Tools for Stroke and Dementia in Patients with Atrial Fibrillation

  • Arrhythmias (J. Bunch, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

With the aging population, atrial fibrillation (AF) associations with both stroke and dementia have become a priority for the healthcare system. The purpose of this paper is to review the emerging role of clinical scores and biomarkers in the risk stratification of AF patients for risk of stroke and risk of dementia.

Recent Findings

AF is the most common arrhythmia in the aging population and a common comorbidity in atherosclerotic disease and heart failure. In this review, we identified 34 most relevant papers that specifically address the role of biomarkers in risk-stratifying patients with AF with regard to stroke and dementia. Recent data suggest an incremental value for biomarkers of myocardial injury, myocardial strain, and hemostasis for risk-stratifying patients at risk with AF at greater risk of stroke. Furthermore, biomarker risk scores such as the Intermountain Risk Score are emerging as complementary to the commonly used CHA2DS2-VASc score for both stroke and dementia. Imaging biomarkers including left atrial size and left atrial reservoir strain may complement these circulating biomarkers to identify patients at greater risk of stroke, and the combination of AF and evidence of subclinical stroke could further inform the risk cognitive decline.

Summary

Several clinical biomarker risk scores and biomarkers can complement the risk stratification of AF and dementia. With the more frequent use of anticoagulation, developing integrated risk scores for stroke and bleeding in patients with AF is now a focus of ongoing research. Early detection and intervention for cognitive decline in our aging population is also a priority for the healthcare system, and risk scores can help identify higher risk individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The epidemiology of atrial fibrillation and stroke. Cardiol Clin. 2016;34(2):255–68.

    PubMed  Google Scholar 

  2. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JCJ, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–e76.

    PubMed  Google Scholar 

  3. Chao T-F, Liu C-J, Tuan T-C, Chen S-J, Wang K-L, Lin Y-J, et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians? Heart Rhythm. 2016;13(1):46–53.

    PubMed  Google Scholar 

  4. • Graves KG, May HT, Jacobs V, Knowlton KU, Muhlestein JB, Lappe DL, et al. CHA2DS2-VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation. Heart Rhythm. 2019;16(1):3–9 Graves et al. evaluated the association of the CHA2DS2-VASc Score and IMRS with incident dementia in patients with atrial fibrillation and no history of dementia. The authors provide evidence that both risk scores were independently associated with the onset of dementia. Patients in three categories of CHA2DS2-VASc were further stratified by IMRS, especially when CHA2DS2-VASc indicated that risk was low.

    PubMed  Google Scholar 

  5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.

    CAS  PubMed  Google Scholar 

  6. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

    PubMed  Google Scholar 

  7. Nishtala A, Piers RJ, Himali JJ, Beiser AS, Davis-Plourde KL, Saczynski JS, et al. Atrial fibrillation and cognitive decline in the Framingham Heart Study. Heart Rhythm. 2018;15(2):166–72.

    PubMed  Google Scholar 

  8. Jacobs V, Cutler MJ, Day JD, Bunch TJ. Atrial fibrillation and dementia. Trends Cardiovasc Med. 2015;25(1):44–51.

    PubMed  Google Scholar 

  9. Chen LY, Norby FL, Gottesman RF, Mosley TH, Soliman EZ, Agarwal SK, et al. Association of atrial fibrillation with cognitive decline and dementia over 20 years: the ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study). J Am Heart Assoc. 2018;7(6):e007301.

    PubMed  PubMed Central  Google Scholar 

  10. Singh-Manoux A, Fayosse A, Sabia S, Canonico M, Bobak M, Elbaz A, et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. Eur Heart J. 2017;38(34):2612–8.

    PubMed  PubMed Central  Google Scholar 

  11. Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, et al. Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation. 2016;134(22):1697–707.

    CAS  PubMed  Google Scholar 

  12. Rivera-Caravaca JM, Marin F, Vilchez JA, Galvez J, Esteve-Pastor MA, Vicente V, et al. Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores. Stroke. 2019;50(6):1372–9.

    CAS  PubMed  Google Scholar 

  13. Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, et al. Use of biomarkers to predict specific causes of death in patients with atrial fibrillation. Circulation. 2018;138(16):1666–76.

    PubMed  Google Scholar 

  14. Paulin BK, Cedric KK, Tamomh AG, Hui YD. Assessment of cardiac biomarkers (troponin, B-type natriuretic peptide, and D-dimer) in patients with non-valvular atrial fibrillation and stroke. Int J Health Sci (Qassim). 2019;13(6):3–12.

    Google Scholar 

  15. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014;63(1):52–61.

    CAS  PubMed  Google Scholar 

  16. Hayashi K, Tsuda T, Nomura A, Fujino N, Nohara A, Sakata K, et al. Impact of b-type natriuretic peptide level on risk stratification of thromboembolism and death in patients with nonvalvular atrial fibrillation- The Hokuriku-Plus AF Registry. Circ J. 2018;82(5):1271–8.

    CAS  PubMed  Google Scholar 

  17. Roldan V, Vilchez JA, Manzano-Fernandez S, Jover E, Galvez J, Puche CM, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke. 2014;45(3):696–701.

    CAS  PubMed  Google Scholar 

  18. Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, et al. Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RE-LY Trial. J Am Heart Assoc. 2019;8(2):e010107.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Tanaka S, Hirai T, Inao K, Fukuda N, Nakagawa K, Inoue H, et al. High cardiac troponin I is associated with transesophageal echocardiographic risk of thromboembolism and ischemic stroke events in non-valvular atrial fibrillation patients. Circ J. 2018;82(6):1699–704.

    CAS  PubMed  Google Scholar 

  20. Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, Hill SA, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev. 2014;19(4):453–70.

    CAS  PubMed  Google Scholar 

  21. Kang S-H, Park JJ, Choi D-J, Yoon C-H, Oh I-Y, Kang S-M, et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart. 2015;101(23):1881–8.

    CAS  PubMed  Google Scholar 

  22. Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, et al. Asymmetric and symmetric dimethylarginine predict outcomes in patients with atrial fibrillation. An ARISTOTLE Substudy. J Am Coll Cardiol. 2018;72:721–33.

    PubMed  Google Scholar 

  23. Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92(4):835–41.

    CAS  PubMed  Google Scholar 

  24. Tiwari S, Løchen ML, Jacobsen BK, Hopstock LA, Nyrnes A, Njølstad I, et al. CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromsø study. Open Heart. 2016;3(2):e000439.

    PubMed  PubMed Central  Google Scholar 

  25. Obokata M, Negishi K, Kurosawa K, Tateno R, Tange S, Arai M, et al. Left atrial strain provides incremental value for embolism risk stratification over CHA2DS2-VASc score and indicates prognostic impact in patients with atrial fibrillation. J Am Soc Echocardiogr. 2014;27(7):709–716.e4.

    PubMed  Google Scholar 

  26. Leung M, van Rosendael PJ, Abou R, Marsan NA, Leung DY, Delgado V, et al. Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry. Eur Heart J. 2018;39(16):1416–25.

    PubMed  Google Scholar 

  27. Kamel H, Bartz TM, Elkind MSV, Okin PM, Thacker EL, Patton KK, et al. Atrial cardiopathy and the risk of ischemic stroke in the CHD (Cardiovascular Health Study). Stroke. 2018;49:980–6.

    PubMed  PubMed Central  Google Scholar 

  28. Saliba W, Barnett-Griness O, Elias M, Rennert G. Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: a cohort study. Heart Rhythm. 2015;12(5):886–92.

    CAS  PubMed  Google Scholar 

  29. He H, Guo J, Zhang A. The value of urine albumin in predicting thromboembolic events for patients with non-valvular atrial fibrillation. Int J Cardiol. 2016;221:827–30.

    PubMed  Google Scholar 

  30. Saliba W, Barnett-Griness O, Elias M, Rennert G. The association between red cell distribution width and stroke in patients with atrial fibrillation. Am J Med. 2015;128(2):192.e11–8.

    Google Scholar 

  31. Saliba W, Barnett-Griness O, Elias M, Rennert G. Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: a cohort study. J Thromb Haemost. 2015;13(11):1971–9.

    CAS  PubMed  Google Scholar 

  32. Lyu Q-S, Liu B, Huang C, Huang Y-Q. The association between platelet distribution width and stroke in atrial fibrillation patients. Ann Clin Lab Sci. 2019;49(1):143–7.

    CAS  PubMed  Google Scholar 

  33. Ancedy Y, Berthelot E, Lang S, Ederhy S, Boyer-Chatenet L, Di Angelantonio E, et al. Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation? Arch Cardiovasc Dis. 2018;111(5):357–69.

    PubMed  Google Scholar 

  34. Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015;170:1151–60.

    CAS  PubMed  Google Scholar 

  35. Choi SW, Kim BB, Choi DH, Park G, Shin BC, Song H, et al. Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation. Clin Cardiol. 2017;40(11):1013–9.

    PubMed  PubMed Central  Google Scholar 

  36. You L-R, Tang M. The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients: a retrospective study. Medicine (Baltimore). 2018;97(43):e12622.

    CAS  Google Scholar 

  37. Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. J Thromb Haemost. 2014;12(9):1401–12.

    CAS  PubMed  Google Scholar 

  38. Hu X, Wang J, Li Y, Wu J, Qiao S, Xu S, et al. The β-fibrinogen gene 455G/A polymorphism associated with cardioembolic stroke in atrial fibrillation with low CHA2DS2-VASc score. Sci Rep. 2017;7:17517.

    PubMed  PubMed Central  Google Scholar 

  39. Roldán V, Rivera-Caravaca JM, Shantsila A, García-Fernández A, Esteve-Pastor MA, Vilchez JA, et al. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers. Ann Med. 2018;50(1):26–34.

    PubMed  Google Scholar 

  40. Garcia-Fernandez A, Roldan V, Rivera-Caravaca JM, Hernandez-Romero D, Valdes M, Vicente V, et al. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep. 2017;7:41565.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Liang Z, Dong Z, Guo M, Shen Z, Yin D, Hu S, et al. Trimethylamine N-oxide as a risk marker for ischemic stroke in patients with atrial fibrillation. J Biochem Mol Toxicol. 2019;33(2):e22246.

    PubMed  Google Scholar 

  42. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130(21):1847–58.

    CAS  PubMed  Google Scholar 

  43. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, et al. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Am Heart J. 2017;190:94–103.

    CAS  PubMed  Google Scholar 

  44. Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582–90.

    PubMed  PubMed Central  Google Scholar 

  45. •• Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, et al. Performance of the ABC Scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019;139:760–71 Berg et al. investigated whether the ABC-stroke score or its biomarker components were associated with stroke or SEE in patients with atrial fibrillation who were all receiving oral anticoagulation. The authors found that the ABC-stroke score was more predictive of stroke/SEE than CHA2DS2-VASc. Further, elevated hs-cTnT, NT-proBNP, and GDF-15 were significantly associated with stroke/SEE.

    PubMed  PubMed Central  Google Scholar 

  46. • Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, GYH L, et al. Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-Stroke and CHA2DS2-VASc scores. J Am Heart Assoc. 2017;6:e006490 Rivera-Caravaca et al. addressed whether the ABC-stroke score predicted ischemic stroke in patients with atrial fibrillation who were all on stable therapy with a vitamin K antagonist. At 3.5 years of follow-up, the ABC-stroke score was more predictive of stroke than CHA2DS2-VASc, but at 6.5 years the two scores were not different. Other measures of improvement in prediction, however, showed no difference at both timepoints.

    PubMed  PubMed Central  Google Scholar 

  47. Horne BD, May HT, Muhlestein JB, Ronnow BS, Lappe DL, Renlund DG, et al. Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med. 2009;122(6):550–8.

    PubMed  Google Scholar 

  48. Graves KG, May HT, Knowlton KU, Muhlestein JB, Jacobs V, Lappé DL, et al. Improving CHA2DS2-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Risk Score among atrial fibrillation patients. Open Heart. 2018;5:e000907.

    PubMed  PubMed Central  Google Scholar 

  49. •• Horne BD, Jacobs V, May HT, Graves KG, Bunch TJ. Augmented intelligence decision tool for stroke prediction combines factors from CHA2DS2-VASc and the intermountain risk score for patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30(9):1452–61 Horne et al. developed a new hybrid biomarker-comorbidity risk score in patients with atrial fibrillation, 10% of whom were on oral anticoagulation. The hybrid score was named the IMRS-VASc score and utilized the biomarker risk predictors from IMRS and the comorbidity factors from the CHA2DS2-VASc score. The IMRS-VASc score was more predictive of stroke than the CHADS2 or CHA2DS2-VASc scores.

    PubMed  Google Scholar 

  50. Ruff CT, Giugliano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, et al. Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: a subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2016;1(9):999–1006.

    PubMed  Google Scholar 

  51. Piers RJ, Nishtala A, Preis SR, DeCarli C, Wolf PA, Benjamin EJ, et al. Association between atrial fibrillation and volumetric magnetic resonance imaging brain measures: Framingham Offspring Study. Heart Rhythm. 2016;13(10):2020–4.

    PubMed  PubMed Central  Google Scholar 

  52. Caruso P, Signori R, Moretti R. Small vessel disease to subcortical dementia: a dynamic model, which interfaces aging, cholinergic dysregulation and the neurovascular unit. Vasc Health Risk Manag. 2019;15:259–81.

    PubMed  PubMed Central  Google Scholar 

  53. Berman JP, Norby FL, Mosley T, Soliman EZ, Gottesman RF, Lutsey PL, et al. Atrial fibrillation and brain magnetic resonance imaging abnormalities. The ARIC Study. Stroke. 2019;50:783–8.

    PubMed  PubMed Central  Google Scholar 

  54. Graff-Radford J, Madhavan M, Vemuri P, Rabinstein AA, Cha RH, Mielke MM, et al. Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimers Dement. 2016;12(4):391–8.

    PubMed  Google Scholar 

  55. Bunch TJ, Galenko O, Graves KG, Jacobs V, May HT. Atrial fibrillation and dementia: exploring the association, defining risks and improving outcomes. Arrhythmia Electrophysiol Rev. 2019;8(1):8–12.

    Google Scholar 

  56. Rollo J, Knight S, May HT, Anderson JL, Muhlestein JB, Bunch TJ, et al. Incidence of dementia in relation to genetic variants at PITX2, ZFHX3, and ApoE ε4 in atrial fibrillation patients. Pacing Clin Electrophysiol. 2015;38(2):171–7.

    PubMed  Google Scholar 

  57. Bunch TJ, Jacobs V, May H, Stevens SM, Crandall B, Cutler M, et al. Rationale and design of the impact of anticoagulation therapy on the cognitive decline and dementia in patients with nonvalvular atrial fibrillation (CAF) trial: a vanguard study. Clin Cardiol. 2019;42(5):506–12.

    PubMed  PubMed Central  Google Scholar 

  58. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249–54.

    CAS  PubMed  Google Scholar 

  59. Palmquist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772–81. https://doi.org/10.1001/jama.2020.12134.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stanford University School of Medicine, Stanford, CA, USA

    Kalyani A. Boralkar, Francois Haddad & Benjamin D. Horne

  2. Intermountain Medical Center Heart Institute, 5121 S. Cottonwood St., Salt Lake City, UT, 84107, USA

    Benjamin D. Horne

Authors
  1. Kalyani A. Boralkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francois Haddad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin D. Horne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin D. Horne.

Ethics declarations

Conflict of Interest

Kalyani A Boralkar declares that she has no conflict of interest.

Francois Haddad declares that he has no conflict of interest.

Benjamin D Horne is an inventor of clinical decision tools that are licensed to CareCentra and Alluceo; is the PI of risk prediction projects funded by the Intermountain Healthcare’s Foundry innovation program, the Intermountain Research and Medical Foundation, CareCentra, GlaxoSmithKline, and AstraZeneca; and is an investigator on a grant funded by the Patient-Centered Outcomes Research Institute.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Arrhythmias

Electronic Supplementary Material

ESM 1

(DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boralkar, K.A., Haddad, F. & Horne, B.D. Biomarkers and Risk Prediction Tools for Stroke and Dementia in Patients with Atrial Fibrillation. Curr Cardiovasc Risk Rep 14, 23 (2020). https://doi.org/10.1007/s12170-020-00658-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12170-020-00658-0

Keywords

Search

Navigation